3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Dermatologic
2
Conditions
Neoplasms
2
Mycosis Fungoides
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Interventions
Cyclophosphamide
390
Carboplatin
343
Gemcitabine
331
pembrolizumab
330
Cisplatin
327
Paclitaxel
295
Radiotherapy
292
Docetaxel
286
Bevacizumab
249
Rituximab
233
Capecitabine
222
Nivolumab
220
Dexamethasone
205
Fluorouracil
189
fludarabine
178
Oxaliplatin
177
Pemetrexed
153
Doxorubicin
152
Irinotecan
147
Etoposide
144
Leucovorin
143
Cytarabine
134
fludarabine phosphate
129
Bortezomib
129
Cetuximab
127
Lenalidomide
125
Filgrastim
120
Erlotinib Hydrochloride
119
Temozolomide
111
Ipilimumab
111
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Interventional
×
cobomarsen
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts
NCT03837457
2020-11-19
PRISM
miRagen Therapeutics, Inc.
Phase 2
Terminated
8 enrolled